3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
337
Neoplasms, Plasma Cell
56
Precursor Cell Lymphoblastic Leukemia-Lymphoma
54
Recurrence
50
Lymphoma
48
Leukemia
39
Neoplasms
27
Lymphoma, Mantle-Cell
27
Burkitt Lymphoma
26
Lymphoma, Large B-Cell, Diffuse
23
Immunoglobulin Light-chain Amyloidosis
23
Lymphoma, Non-Hodgkin
22
Waldenstrom Macroglobulinemia
21
Lymphoma, Follicular
17
Leukemia, Lymphocytic, Chronic, B-Cell
16
Hodgkin Disease
14
Nausea
12
Lymphoma, Extranodal NK-T-Cell
12
Lymphoma, B-Cell, Marginal Zone
12
Vomiting
11
Smoldering Multiple Myeloma
11
Prostatic Neoplasms
11
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
11
Breast Neoplasms
11
Renal Insufficiency
10
Neoplasm Metastasis
9
Lymphoma, Large-Cell, Immunoblastic
9
Carcinoma, Non-Small-Cell Lung
9
Lung Neoplasms
8
Leukemia, Biphenotypic, Acute
7
Interventions
varlilumab
1
daratumumab
1
belantamab mafodotin
1
Vincristine
1
Rituximab
1
Prednisone
1
Nivolumab
1
Immunoglobulin G
1
Etoposide
1
Doxorubicin
1
Disulfides
1
Dexamethasone
1
Cyclophosphamide
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Plasmablastic Lymphoma
×
Dexamethasone
×
Clear all
NCT04915248
2025-12-24
FIL_DALYA
Fondazione Italiana Linfomi - ETS
Phase 2
Recruiting
28 enrolled